Held in Chicago, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together professionals in oncology from around the world to present the latest clinical research. These advancements are critical for unlocking personalized treatment options for patients with non-small cell lung cancer (NSCLC).
To help you stay informed on the latest innovations, we’ve gathered some of the key breakthroughs unveiled at this conference.
As a reminder, neoadjuvant refers to a therapy or treatment received BEFORE surgery to treat your cancer. An adjuvant treatment occurs after the initial treatment–most likely a surgery. Progression-free survival is the period of time after starting treatment that patients live without the cancer getting worse or spreading.
Sevabertinib showed promising responses in patients with HER2-mutant NSCLC from the phase 1/2 SOHO-01 trial. This study included patients who had received previous treatment but had never received targeted HER2 therapy before, as well as patients who didn’t receive any treatment for advanced disease. This is significant because there are few treatment options for HER2-mutant NSCLC and sevabertinib could benefit this population. Sevabertinib has been granted priority review by the FDA.
According to the phase 3 MARIPOSA-2 trial, for patients with EGFR-mutated NSCLC experiencing disease progression on or after osimertinib, amivantamab in combination with chemotherapy significantly improved median progression-free survival. These results mean patients who are resistant to osimertinib may have more treatment options.
Results from the phase 2 KRYSTAL-7 trial revealed adagrasib plus pembrolizumab improved measures of efficacy in patients with KRAS G12C–mutated NSCLC. This is significant because these findings mean adagrasib plus pembrolizumab could provide new treatment options in this subgroup.
Data from the AIM-HIGH trial showed that a molecular test could identify high-risk early-stage NSCLC patients who would benefit from chemotherapy after surgery. After 24 months, 96% of participants who received chemotherapy were alive with no disease progression. This is significant because it provides clarity on who would benefit from chemotherapy after surgery to reduce recurrence.
Stay informed on the latest news in lung cancer research and download the Outcomes4Me app. Enable notifications so we can send you important updates.
